Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Janssen's Lebowitz On J&J's Oncology Expansion Plans Outside Of Hematology

Executive Summary

Janssen global oncology therapeutic area head Peter Lebowitz talked to Scrip about the company's next big ambitions in lung, bladder and prostate cancer.

You may also be interested in...



Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna’s co-founder shares tips on innovation.

No Way To Go But Grow: J&J Outlines Plans To Become A $60bn Pharma In 2025

Management outlined its growth strategy to investors, highlighting plans to file 14 novel drugs with more than $1bn in peak sales by 2025.

J&J’s Consumer Health Spinout Plan Surprises, But Seen As Sensible

Analysts say the pharma’s plan would separate out a unit with less growth and lower margins – and some predict a further breakup of the pharma and medical device units.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145436

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel